Skip to main content
Premium Trial:

Request an Annual Quote

Palex Medical to Distribute Molecular Detection's MRSA Test in Spain

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular Detection and Palex Medical today announced an exclusive agreement, under which Palex will distribute MDI's Detect-Ready MRSA test in Spain.

Palex, a Spanish distributor of medical devices and diagnostic products, recently launched the test in Spain, the companies said in a statement. Financial terms of the deal were not announced.

The Detect-Ready test is a real-time PCR in vitro diagnostic test for the direct detection of methicilllin-resistant Staphylococcus aureus nasal colonization. Unlike other MRSA tests, the Detect-Ready kit are off-the-shelf, room-temperature-stabilized, and require no refrigeration, the two firms said. It also is compatible with several real-time PCR platforms.

In May, MDI and Launch Diagnostics announced a distribution agreement for the test in the UK, France, and Republic or Ireland. The test is also available in Germany, Switzerland, and Austria.

Last month, MDI said it had raised $1.4 million in a follow on to a Series C round of financing.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.